YIDEYICO

Yideyi Pharmaceutical (YIDEYICO) is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of novel small molecule therapeutics for autoimmune and inflammatory diseases. The company's core expertise lies in the design of highly selective kinase inhibitors, with a primary focus on the Janus kinase (JAK) family. Its lead candidate, YDY-101, is a potent and selective TYK2 inhibitor currently in Phase 2 clinical trials for the treatment of moderate-to-severe plaque psoriasis. Yideyi's pipeline also includes several early-stage programs targeting other key pathways in immune-mediated disorders. The company is committed to advancing precision medicine to improve the lives of patients with chronic inflammatory conditions.